LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
41.13
-1.06 (-2.51%)
Aug 1, 2025, 4:00 PM - Market closed
Chimerix Revenue
LivaNova had revenue of $316.86M in the quarter ending March 31, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to $1.28B, up 7.62% year-over-year. In the year 2024, LivaNova had annual revenue of $1.25B with 8.66% growth.
Revenue (ttm)
$1.28B
Revenue Growth
+7.62%
P/S Ratio
1.75
Revenue / Employee
$439,786
Employees
2,900
Market Cap
2.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.25B | 99.89M | 8.66% |
| Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
| Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
| Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
| Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
LIVN News
- 24 days ago - LivaNova to Announce Second-Quarter 2025 Results - Business Wire
- 25 days ago - LivaNova: The Sell-Off Is Excessive Here - Seeking Alpha
- 2 months ago - CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - Business Wire
- 2 months ago - LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - Business Wire
- 2 months ago - LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - Business Wire
- 2 months ago - LivaNova to Present at the Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance - Business Wire